Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

370.95 -1.32 (-0.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 206,480
Open 370.00
Bid (Size) 148.38 (2)
Ask (Size) 400.00 (4)
Prev. Close 372.27
Today's Range 370.00 - 373.83
52wk Range 256.44 - 407.93
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
From argenx SE
Via Globe NewsWire

Performance

YTD
-0.76%
-0.76%
1 Month
-1.29%
-1.29%
3 Month
+2.39%
+2.39%
6 Month
+1.19%
+1.19%
1 Year
+28.67%
+28.67%

More News

Read More
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
From argenx SE
Via Globe NewsWire
Analyst Ratings for argenx
Via Benzinga
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Expert Ratings for argenx
Via Benzinga
7 Analysts Have This to Say About argenx
Via Benzinga
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
From argenx SE
Via Globe NewsWire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
From argenx SE
Via Globe NewsWire
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Via Benzinga
argenx Appoints Ana Cespedes to Board of Directors
From argenx SE
Via Globe NewsWire
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
From argenx SE
Via Globe NewsWire
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Via Benzinga
argenx Enters Into Agreement To Acquire Priority Review Voucher
From argenx SE
Via Globe NewsWire
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
Via Benzinga
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
From argenx SE
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via Globe NewsWire
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Via Benzinga
Recap: argenx Q3 Earnings
Via Benzinga
argenx Reports Third Quarter 2022 Financial Results and Provides Business Update
From argenx SE
Via Globe NewsWire
argenx to Report Third Quarter 2022 Financial Results and Business Update on October 27, 2022
From argenx SE
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Via Benzinga
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.